Cancer Screening and Treatment in the U.S. in 2026: Breast, Colorectal and Lung Cancer Guide
"A 2026 guide to cancer screening, diagnosis, treatment, biomarker testing, and insurance coverage in the United States."
 |
| Illustration. A doctor explains cancer examination and treatment to a patient at a hospital. |
Cancer screening in the United States is increasingly focused on finding cancer early, identifying people at higher risk, and matching treatment to the biology of each tumor.
The American Cancer Society estimates that 2,114,850 new cancer cases and 626,140 cancer deaths will occur in the United States in 2026.
That represents approximately 5,800 new cancer diagnoses each day.
The figures are projections based on the latest available cancer incidence and mortality data, rather than a final count of cases diagnosed during 2026.
At the same time, the U.S. cancer death rate has fallen substantially over the long term.
The American Cancer Society reports that the cancer mortality rate has declined 34% from its peak in 1991, with an estimated 4.8 million cancer deaths averted over that period.
This guide explains how cancer screening, diagnosis, treatment, biomarker testing and insurance coverage work in the U.S., with a focus on three major cancers: breast cancer, colorectal cancer and lung cancer.
Medical information: This article is for educational purposes and does not replace individualized medical advice. Screening recommendations can differ based on age, risk factors, symptoms, medical history and the organization issuing the guideline.
Cancer Screening vs. Cancer Diagnosis: What's the Difference?
One of the most important distinctions for patients is the difference between screening and diagnostic testing.
Cancer screening
Screening is performed in people who generally do not have symptoms of the cancer being screened for.
The goal is to find cancer or precancerous changes before symptoms develop.
Examples include:
mammography for breast cancer;
stool-based testing or colonoscopy for colorectal cancer;
low-dose CT for lung cancer in eligible high-risk adults.
Diagnostic testing
Diagnostic testing is performed when there is a symptom, abnormal screening result, suspicious imaging finding or another reason to investigate a possible disease.
Examples include:
diagnostic mammography after an abnormal screening mammogram;
colonoscopy after a positive stool-based colorectal screening test;
biopsy of a suspicious lung nodule.
This distinction matters because insurance coverage and patient cost-sharing can differ between preventive screening and diagnostic follow-up. The National Cancer Institute specifically notes that a colonoscopy performed after a positive colorectal screening test may be treated as a diagnostic examination rather than a preventive screening procedure.
Breast Cancer Screening in the U.S.
Breast cancer is one of the most commonly diagnosed cancers among women in the United States.
For people at average risk, mammography remains the primary screening tool.
How often should you get a mammogram?
There is an important difference between major U.S. guidelines.
American Cancer Society
For women at average risk, the American Cancer Society recommends:
Age 40–44: the option to begin annual mammography.
Age 45–54: annual mammography.
Age 55 and older: mammography every two years or continued annual screening.
Screening should continue while a woman is in good health and expected to live at least 10 more years.
USPSTF
The U.S. Preventive Services Task Force recommends:
Mammography every two years for women ages 40–74.
The CDC also currently summarizes the USPSTF recommendation as biennial mammography for women ages 40–74 at average risk.
Why are the recommendations different?
Medical organizations can reach different recommendations because they weigh evidence, benefits, harms, false positives and overdiagnosis differently.
For that reason, patients should discuss their individual screening schedule with their healthcare provider rather than assuming that one schedule applies to everyone.
Who may need additional breast screening?
Women at substantially higher risk may need more than routine mammography.
The ACS recommends annual breast MRI plus mammography, typically beginning around age 30, for certain high-risk women, including those whose estimated lifetime breast cancer risk is about 20%–25% or greater based on appropriate risk assessment tools.
High-risk factors can include certain inherited genetic variants and a history of chest radiation at a young age.
Breast Cancer Diagnosis
A screening mammogram does not by itself establish a cancer diagnosis.
An abnormal screening result may lead to:
additional mammographic views;
breast ultrasound;
MRI in selected circumstances;
biopsy.
If cancer is diagnosed, the tumor may be tested for biomarkers that help guide treatment.
The National Cancer Institute notes that breast tumors are commonly evaluated for estrogen receptor (ER), progesterone receptor (PR) and HER2. Other biomarkers, including Ki-67, may also be evaluated in appropriate cases.
Newer Breast Cancer Treatments in 2026
Cancer treatment is increasingly tailored to tumor biology rather than based only on the organ where the cancer began.
One example is the FDA's May 2026 approval of fam-trastuzumab deruxtecan-nxki (Enhertu) for two indications involving HER2-positive early-stage breast cancer.
The approved uses include:
neoadjuvant treatment for adults with HER2-positive stage II or III breast cancer, followed by a specified regimen; and
adjuvant treatment for certain patients with residual invasive disease after neoadjuvant therapy.
Another 2026 development is vepdegestrant (Veppanu).
The FDA approved vepdegestrant on May 1, 2026, for adults with:
ER-positive;
HER2-negative;
ESR1-mutated;
advanced or metastatic breast cancer;
when the disease has progressed after at least one line of endocrine therapy. An FDA-authorized test is used to identify the relevant ESR1 mutation.
These drugs are not treatments for every breast cancer patient. Their use depends on tumor biomarkers, disease stage, previous treatment and other clinical factors.
Colorectal Cancer Screening in the U.S.
Colorectal cancer includes cancers of the colon and rectum.
The American Cancer Society updated its colorectal cancer screening guideline in 2026.
When should colorectal cancer screening start?
For adults at average risk, ACS recommends beginning screening at age 45 and continuing through age 75 for people with a life expectancy greater than 10 years. Adults ages 76–85 should discuss whether continued screening is appropriate with their healthcare provider.
People with a strong family history, certain inherited syndromes, inflammatory bowel disease or a previous history of colorectal cancer or certain polyps may need a different screening strategy.
Colorectal Cancer Screening Options
There is no single screening test that every person must use.
Colonoscopy
For average-risk adults, colonoscopy is commonly performed every 10 years when used as the primary screening method.
One major advantage is that physicians can identify and remove many polyps during the same procedure.
FIT
The fecal immunochemical test is a stool-based screening test that is generally performed annually.
Multitarget stool DNA
Multitarget stool DNA testing, such as Cologuard, is performed every three years under current ACS guidance for appropriate average-risk patients.
Multitarget stool RNA
The 2026 ACS guideline added multitarget stool RNA testing as another at-home option, also at a three-year interval.
Blood-based testing
Blood-based colorectal cancer screening is now included among ACS-recommended options.
However, ACS does not consider blood-based testing a preferred option at this time because available evidence shows lower sensitivity for advanced precancerous lesions and stage I cancers compared with established stool-based tests.
What Happens After a Positive Colorectal Cancer Screening Test?
A positive stool or blood-based screening test does not automatically mean that you have cancer.
It does mean that additional evaluation is necessary.
The ACS 2026 guideline states that positive non-colonoscopy screening tests should be followed by a timely colonoscopy, preferably within six months, to complete the screening process.
This is an important distinction:
At-home test → screening
Positive result → diagnostic follow-up
The two steps should not be treated as interchangeable.
Newer Colorectal Cancer Treatments
Modern colorectal cancer treatment increasingly uses biomarker information.
The National Cancer Institute explains that biomarker testing can help doctors identify treatments that are more likely to work for an individual tumor. Biomarker testing is routinely used in certain cancers, including colorectal, breast and non-small cell lung cancer.
One example is BRAF V600E-mutated metastatic colorectal cancer.
On February 24, 2026, the FDA granted traditional approval to encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for adults with metastatic colorectal cancer containing a BRAF V600E mutation identified by an FDA-authorized test.
The approval is specifically for the biomarker-defined metastatic population. It should not be interpreted as a treatment for colorectal cancer generally.
Lung Cancer Screening in the U.S.
Lung cancer screening is targeted at people with a significant smoking history because routine screening is not recommended for the general population.
The ACS recommends annual low-dose CT screening for people who:
are 50–80 years old;
currently smoke or previously smoked; and
have at least a 20 pack-year smoking history.
A pack-year represents smoking approximately one pack of cigarettes per day for one year.
For example:
1 pack per day × 20 years = 20 pack-years.
2 packs per day × 10 years = 20 pack-years.
People considering screening should discuss the potential benefits, limitations and harms with a healthcare professional. ACS also emphasizes smoking cessation for people who currently smoke.
What Is a Low-Dose CT Lung Cancer Screening?
A low-dose CT, or LDCT, uses a lower radiation dose than a standard diagnostic CT scan.
The purpose of screening is to identify suspicious lung abnormalities before symptoms develop.
An abnormal scan does not automatically mean lung cancer.
Depending on the finding, follow-up may include:
repeat CT imaging;
PET imaging;
bronchoscopy;
biopsy;
or other diagnostic procedures.
Biomarker Testing and Lung Cancer Treatment
For non-small cell lung cancer (NSCLC), biomarker testing can be particularly important.
Depending on the cancer and clinical situation, testing may evaluate alterations involving genes such as:
EGFR;
ALK;
ROS1;
BRAF;
KRAS;
MET;
RET;
NTRK;
HER2/ERBB2;
and other biomarkers.
The NCI describes biomarker testing as a tool that can help doctors select treatments more likely to benefit a particular patient.
Zongertinib
On February 26, 2026, the FDA granted accelerated approval to zongertinib (Hernexeos) for adults with unresectable or metastatic non-squamous NSCLC whose tumors have activating HER2/ERBB2 tyrosine kinase domain mutations identified by an FDA-authorized test.
This is a biomarker-defined treatment, not a general lung cancer therapy.
Sunvozertinib
The FDA granted accelerated approval to sunvozertinib (Zegfrovy) in July 2025 for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after progression on or after platinum-based chemotherapy.
Because the drug received accelerated approval, confirmatory clinical research remains part of the regulatory process.
Perioperative immunotherapy
Treatment for some resectable NSCLC cases can involve therapy before and after surgery.
For example, the FDA approved durvalumab with platinum-containing chemotherapy as neoadjuvant treatment followed by durvalumab after surgery for certain adults with resectable NSCLC who do not have known EGFR mutations or ALK rearrangements.
This illustrates the broader shift toward perioperative cancer treatment, in which systemic therapy may be incorporated before surgery rather than being reserved only for disease that cannot be removed surgically.
At-Home Cancer Screening in the U.S.
At-home testing is becoming an increasingly important part of cancer screening, but it does not mean every cancer can be screened for at home.
Colorectal cancer
At-home stool-based screening is an established option for appropriate average-risk adults.
Examples include:
FIT;
multitarget stool DNA;
multitarget stool RNA.
A positive result requires follow-up colonoscopy.
Breast cancer
There is no at-home test that replaces mammography for routine breast cancer screening.
Breast self-awareness can help people recognize changes, but it is not a substitute for recommended screening mammography.
Lung cancer
There is no at-home test that replaces LDCT for eligible high-risk adults.
Cancer Screening and Health Insurance in the U.S.
Cancer screening coverage can be confusing because the financial rules may change depending on whether a service is classified as:
preventive screening;
diagnostic evaluation; or
treatment.
Marketplace and many private health plans
HealthCare.gov states that most health plans must cover certain preventive services, including recommended screening tests, without cost-sharing when the applicable requirements are met.
Generally, this applies when the service is provided by an in-network provider, although coverage rules and exceptions can apply.
Therefore, it is inaccurate to say that every cancer-related medical service is automatically free.
After an abnormal screening result
A diagnostic procedure following an abnormal screening result can be treated differently from preventive screening.
For example, NCI notes that a colonoscopy performed after a positive colorectal screening test may be considered diagnostic and may not receive the same cost treatment as an initial screening colonoscopy.
Patients should therefore check their plan before testing and ask how a potential follow-up procedure would be classified.
Medicare Cancer Screening Coverage
Medicare Part B covers many preventive and cancer screening services.
Medicare's current preventive-services information includes:
mammograms;
colorectal cancer screening;
lung cancer screening;
blood-based colorectal screening;
stool-based screening;
and other preventive services.
For eligible beneficiaries, Medicare generally covers many preventive services at no cost when the provider accepts assignment.
For lung cancer screening, Medicare Part B currently covers annual LDCT for eligible beneficiaries meeting its specific criteria, including age 50–77, being asymptomatic, having a current or recent smoking history, having at least 20 pack-years, and receiving an order from a healthcare provider.
Medicare coverage rules can differ from ACS screening recommendations. For example, ACS recommends lung cancer screening through age 80, while Medicare's current Part B eligibility extends through age 77.
That distinction is important for older adults.
2026 Marketplace Out-of-Pocket Maximum
For Marketplace health plans, HealthCare.gov lists the 2026 maximum out-of-pocket limit as:
$10,600 for an individual
$21,200 for a family
The limit applies to covered services and in-network care under the applicable plan. It does not include premiums, out-of-network care or services that the plan does not cover.
This figure should not be presented as a universal maximum for every U.S. cancer patient because insurance arrangements differ.
How Much Does Cancer Treatment Cost in the U.S.?
There is no single national price for cancer treatment.
The final amount a patient pays can depend on:
cancer type;
stage;
treatment regimen;
hospital;
geographic location;
insurance plan;
deductible;
coinsurance;
provider network;
drug coverage;
Medicare or Medicaid eligibility;
and financial assistance.
For that reason, a national article should be cautious about publishing a single dollar amount for chemotherapy, immunotherapy or cancer surgery as though it were a standard price.
A more useful question for patients is:
"What will my insurance-covered treatment cost me out of pocket?"
Patients should ask their insurer and treatment center for a written estimate whenever possible.
Questions to Ask Your Doctor About Cancer Screening
Before deciding on a screening test, patients can ask:
Am I at average or increased risk?
Which screening test is recommended for someone with my age and risk factors?
How often should I be screened?
What are the possible benefits and harms?
What happens if the result is abnormal?
Will I need a diagnostic test?
How will my insurance classify the test?
What will I likely pay out of pocket?
If cancer is diagnosed, should my tumor undergo biomarker testing?
Are there clinical trials or targeted treatments appropriate for my cancer?
The Bottom Line
Cancer screening in the United States is becoming more personalized.
For breast cancer, major organizations recommend mammography beginning at age 40, although the recommended frequency differs between ACS and USPSTF guidance.
For colorectal cancer, ACS recommends screening average-risk adults beginning at age 45 and now includes additional stool and blood-based options in its 2026 guideline. Positive non-colonoscopy tests require timely follow-up colonoscopy.
For lung cancer, annual LDCT is recommended for adults who meet specific age and smoking-history criteria.
Treatment is also becoming increasingly dependent on tumor biology. Biomarker testing can help identify patients who may benefit from targeted therapies or immunotherapies, while new FDA approvals in 2025 and 2026 have expanded treatment options for specific molecular subgroups.
The most important point for patients is that there is no single cancer screening schedule or treatment that applies to everyone. Age, symptoms, family history, smoking history, previous diagnoses, biomarkers, overall health and insurance coverage all matter.
Medical Sources
This article is based primarily on information from:
American Cancer Society
U.S. Preventive Services Task Force
Centers for Disease Control and Prevention
U.S. Food and Drug Administration
National Cancer Institute
Centers for Medicare & Medicaid Services
Medicare.gov
HealthCare.gov
Last medically reviewed for source accuracy: October 2026.
Medical disclaimer: This content is intended for general educational purposes only. It does not constitute medical diagnosis or treatment advice. Talk with a qualified healthcare professional about your individual health, screening eligibility and treatment options.